September 22, 2010
Gilenya approved for multiple sclerosis
Data from a two-year placebo-controlled study showed a reduction in relapse rate (54% reduction, p<0.001) and risk of disability progression among Gilenya patients (30% reduction confirmed at 3-month follow-up visit, p=0.02). In both studies, treatment with Gilenya also resulted in statistically significant reductions in brain lesion activity as measured by MRI.
Gilenya will be available in early October in a 0.5mg dosage strength.
For more information call (877) 408-4974 or visit www.gilenya.com.